Pfizer (PFE) Cash from Investing Activities (2009 - 2026)

Pfizer (PFE) has reported Cash from Investing Activities for 18 consecutive years, with $2.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 46.7% year-over-year to $2.1 billion in Q2 2026; TTM through Jun 2026 was -$5.7 billion, a 135.31% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 billion, down 150.94% from the prior year.
• Cash from Investing Activities was $2.1 billion for Q2 2026 at Pfizer, up from $785.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $4.6 billion in Q2 2024 and troughed at -$25.5 billion in Q3 2023.
• A 5-year average of -$2.3 billion and a median of $1.3 billion in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 484.66% in 2023 and tumbled 156.84% in 2025, its largest moves.
• Over 5 years, Cash from Investing Activities stood at -$11.3 billion in 2022, then rose by 2.8% to -$11.0 billion in 2023, then jumped by 138.88% to $4.3 billion in 2024, then tumbled by 243.77% to -$6.1 billion in 2025, then surged by 134.27% to $2.1 billion in 2026.
• The last three Cash from Investing Activities figures came in at $2.1 billion (Q2 2026), $785.0 million (Q1 2026), and -$6.1 billion (Q4 2025), per Business Quant data.